Bacterial Vaginosis: A Complete Guide for Women

Bacterial vaginosis (BV) is one of the most common vaginal conditions affecting women, yet it is still widely misunderstood and under-explained. If you have BV — or recurrent BV that keeps coming back despite treatment — please know that this is not a hygiene failure or something you have done wrong.

This article covers what BV actually is, what drives it, the evidence-based options for managing it (both medical and natural), and how perimenopause and menopause affect the picture — because that connection is rarely discussed.

What Is BV, Really?

BV is not a traditional infection in the way most people think of infections. There is no single bug that "causes" it. It does not work like a urinary tract infection or like thrush. What BV actually represents is a disruption of the normal vaginal ecosystem — a shift in the balance of bacteria that normally live there.

To understand why that matters, let's talk briefly about what a healthy vaginal environment looks like.

Your Vagina Has Its Own Ecosystem

Under healthy conditions, your vagina is dominated by a group of bacteria called Lactobacillus species — these make up around 90–95% of the vaginal flora in most women of reproductive age. These bacteria are not passive residents. They are actively protective. They produce lactic acid, which keeps the vaginal pH low (around 3.8–4.5 — mildly acidic, like yoghurt), and they produce other antimicrobial substances that suppress the growth of potentially harmful bacteria.

I often describe it like a well-tended garden. Lactobacillus are the healthy plants that crowd out the weeds. When they are thriving, the whole ecosystem holds itself in balance.

What Happens in BV

In BV, that balance is disrupted. Lactobacillus numbers drop sharply — sometimes disappearing almost entirely — and a diverse community of anaerobic bacteria (bacteria that thrive in low-oxygen environments) moves in to replace them. These include bacteria with names like Gardnerella vaginalis, Atopobium vaginae, Prevotella, and Mobiluncus, among others.

As the lactobacilli decline, the lactic acid they produce declines with them. Vaginal pH rises. The protective acidic environment gives way to one that is more alkaline — and that is what allows the anaerobic bacteria to grow.

One of the most important things to understand about BV is that these bacteria do not just float around freely. They form biofilms — structured communities that essentially glue themselves to the vaginal lining. Biofilms act like a protective shield. They are resistant to many standard treatments, including some antibiotics. This is one of the core reasons BV keeps coming back.

What Are the Symptoms?

BV can look different in different women, and importantly, up to half of women with BV have no symptoms at all. When symptoms do occur, the most common are:

• A thin, watery, greyish-white discharge 
• A strong, fishy or unpleasant odour — often more noticeable after sex, because semen raises vaginal pH and triggers the release of amines (small, fishy-smelling chemical compounds produced by BV-associated bacteria)
• Some women notice mild irritation or discomfort, though significant itch or soreness is more typical of thrush

What BV does NOT typically cause: the thick, cottage-cheese discharge and intense itch more characteristic of a yeast infection (thrush). These are genuinely different conditions, though they are frequently confused — by women, and sometimes by clinicians.

If you are unsure what you are dealing with, it is always worth seeing a doctor or nurse for proper assessment. Getting the right diagnosis matters, because the treatments are very different.

How Is BV Diagnosed?

In clinical practice, BV is most commonly diagnosed using what is called the Amsel criteria — a set of four clinical findings, three of which need to be present for a diagnosis:

1. Thin, uniform, whitish-grey discharge that coats the vaginal walls
2. Elevated vaginal pH (above 4.5 — your doctor can check this with a simple pH strip)
3. A positive "whiff test" — a fishy odour when a chemical solution is added to a swab of the discharge
4. The presence of "clue cells" under the microscope — these are vaginal cells that are coated with so many bacteria they look speckled

A more precise laboratory method called the Nugent score (which examines vaginal bacteria under a microscope and assigns a score based on what is present) is considered the reference standard but is mainly used in research settings. There are also newer commercial tests, including some PCR-based tests that look at the ratio of protective bacteria to BV-associated bacteria — these are increasingly available and can be helpful in complex cases.

Importantly, routine bacterial swab culture is not always recommended for diagnosing BV. The bacteria involved in BV are also found in healthy vaginas, and standard culture cannot always tell the difference.

What Causes BV? Understanding the Risk Factors

Because BV is a disruption of an ecosystem rather than a straightforward infection, it does not have one single cause. Instead, it is shaped by a combination of biological, behavioural, and environmental factors.

Sexual Activity

BV is strongly associated with sexual activity. Women who have never been sexually active very rarely develop it. The relationship is complex — BV is not classified as a sexually transmitted infection (STI) in the traditional sense, but sexual activity clearly plays a role in both triggering and perpetuating it.

Research has shown that:

• Having a new or multiple male sexual partners increases BV risk
• Having a female sexual partner increases risk even more
• Consistent condom use is protective

And crucially — male sexual partners can carry BV-associated bacteria in their urine and semen. A landmark 2025 randomised controlled trial published in the New England Journal of Medicine found that treating male partners with oral metronidazole and topical clindamycin cream reduced BV recurrence in women from 63% to 35% within 12 weeks. This is striking, and it has significant implications for women with recurrent BV — something I will come back to later.

Vaginal Douching

Douching — using water or commercial products to rinse inside the vagina — is consistently associated with BV. It disrupts the vaginal ecosystem directly. Please don't do it. The vagina is self-cleaning. It does not need to be rinsed, and attempts to do so typically do more harm than good.

Smoking, Stress, and Other Lifestyle Factors

Smoking, obesity, immunosuppression (a weakened immune system, whether from medications or illness), and psychosocial stress have all been associated with changes in the vaginal microbiome and increased BV risk. These are not minor factors. Your body is interconnected — and the state of your overall health influences your vaginal health too.

Genetics and Immune Factors

Not all women are equally susceptible to BV. Your genetics and the immune environment of the vagina likely influence who develops it and how frequently. This helps explain why some women have BV once and never again, while others seem to have it constantly despite doing everything right.

Menopause, Perimenopause, and Your Vaginal Ecosystem

This is something I want to spend real time on, because it is so rarely explained to women.

The vaginal environment is exquisitely sensitive to oestrogen. And during perimenopause and menopause, oestrogen levels decline — often dramatically and unpredictably.

What Oestrogen Does for Your Vagina

Oestrogen supports the vaginal ecosystem in a very specific way. It maintains the thickness of the vaginal lining and, importantly, it promotes the presence of glycogen — a form of sugar that the vaginal cells produce and that Lactobacillus bacteria feed on. Lactobacillus eat glycogen, produce lactic acid, and keep the environment acidic and protective.

When oestrogen declines, glycogen production falls. With less fuel available, Lactobacillus populations diminish. Vaginal pH rises. The environment becomes less acidic — less protective — and more vulnerable to the kind of dysbiosis (imbalance of microbes) seen in BV.

What This Means Practically

Research consistently shows that postmenopausal women have significantly reduced Lactobacillus dominance in the vaginal microbiome compared to premenopausal women, and are more likely to have elevated vaginal pH and a more diverse, potentially problematic bacterial community.

The picture is nuanced. Some studies show lower BV rates in postmenopausal women overall (partly because sexual activity, which drives BV, often changes), while others, including a large 2025 clinic study, show higher rates of BV and vaginal infections in postmenopausal women compared to premenopausal women. What is clear across the research is that the vaginal microbiome changes significantly at menopause, in ways that increase vulnerability.

This change is closely linked to what we call the genitourinary syndrome of menopause (GSM) — the cluster of symptoms including vaginal dryness, irritation, discomfort during sex, and urinary symptoms that many women experience in perimenopause and beyond. Vaginal atrophy (thinning, drying, and inflammation of the vaginal walls due to declining oestrogen) is a key part of this picture. BV and GSM can coexist and can be confused with one another, which is why proper assessment matters.

What Helps: Oestrogen and the Vaginal Ecosystem

The good news is that local vaginal oestrogen — a cream, tablet, or pessary (a small insert that dissolves inside the vagina) applied directly to the vagina — can restore Lactobacillus populations, lower vaginal pH, and improve the atrophy and thinning of the vaginal tissue. This is a safe, well-tolerated, and highly effective option for many women, and very little of the oestrogen is absorbed into the rest of the body.

If you are in perimenopause or postmenopause and experiencing recurrent BV, or vaginal dryness and discomfort that you've been told to just live with — please know that local vaginal oestrogen is worth discussing with your doctor. It is not routinely offered, but it can make a significant difference.

Managing BV: What the Evidence Actually Says

I want to give you a thorough, honest picture here — both the medical options and the natural or supportive approaches, with a clear sense of how strong the evidence is for each.

Standard Medical Treatments

Antibiotics: Effective Short-Term, but With a Catch

Antibiotics remain the most evidence-based first-line treatment for BV. The most commonly prescribed are:

Metronidazole — available as either oral tablets or a vaginal gel. Both are equally effective. Oral metronidazole can cause nausea in some women; if this is an issue for you, the vaginal gel is a good alternative.

Clindamycin — available as a vaginal cream or oral tablets. Note: clindamycin cream can weaken latex condoms and diaphragms — worth knowing.

Other options include secnidazole (a single oral dose) and tinidazole, which have comparable efficacy to metronidazole.

These antibiotics achieve initial cure rates of around 80–90% in the short term. That sounds reassuring. The problem is what happens next.

Recurrence rates are high. Up to 30% of women experience BV again within 3 months of treatment, and up to 58% within 12 months. This is not treatment failure in the traditional sense — the antibiotics generally work. But they clear the bacteria without reliably restoring a healthy Lactobacillus-dominated environment. And importantly, they do nothing to address the biofilm problem or the role of sexual partners. So BV can — and often does — return.

This is one of the most frustrating aspects of BV for the women I see in clinic — being told the course of antibiotics "should have fixed it," and then finding themselves back a few months later, feeling like something must be wrong with them. Nothing is wrong with you. The biology is just more complicated than a single course of antibiotics can address.

Recurrent BV: When It Keeps Coming Back

Recurrent BV is defined as three or more confirmed episodes in a year. It is very common, and it deserves a different, more thoughtful approach than a repeated course of the same antibiotic.

Why Does It Keep Recurring?

Several factors drive recurrence, and understanding them is essential to managing it:

Biofilm persistence. The bacteria involved in BV, particularly Gardnerella vaginalis, form protective biofilms on the vaginal wall that are resistant to antibiotic treatment. Even when symptoms clear, the biofilm can persist and seed a new episode.

Failure to restore healthy flora. Antibiotics kill the BV-associated bacteria but do not replace them with Lactobacillus. Without recolonisation of protective bacteria, the environment remains vulnerable.

Sexual reinfection. As the partner treatment trial mentioned above demonstrated, BV-associated bacteria can be carried by male partners and reintroduced during sex, even after successful treatment of the woman.

Douching and hygiene habits. Continued douching or the use of harsh soaps in the vaginal area perpetuates disruption.

Hormonal factors. Declining oestrogen at perimenopause changes the vaginal environment in ways that make recurrence more likely.

Suppressive Therapy for Recurrent BV

For women with recurrent BV, current guidelines support suppressive maintenance therapy rather than repeated short courses. The most evidence-based approach involves:

A treatment course of antibiotics (metronidazole or tinidazole), followed by twice-weekly intravaginal (inside the vagina) metronidazole gel as ongoing suppression — typically for 4 to 6 months.

Some protocols also incorporate boric acid as part of the suppressive approach — more on that below.

The goal of suppressive therapy is to keep the bacterial load low over time while the vaginal ecosystem has the opportunity to restabilise.

Natural and Adjunctive Approaches: What the Evidence Shows

I want to give you an honest appraisal here. Some of these options have genuinely promising evidence. Others are still early in their research journey. I'll be clear about where we are with each.

Probiotics

The evidence for probiotics in BV is growing and genuinely interesting — though it is not yet definitive.

As an add-on to antibiotics: Multiple systematic reviews and meta-analyses suggest that adding probiotics to antibiotic treatment meaningfully improves cure rates compared to antibiotics alone. One meta-analysis found probiotics improved BV cure rates by around 28% compared to antibiotics alone when used alongside standard treatment.

For preventing recurrence: Some well-designed trials have shown significant promise. A phase III randomised controlled trial found that vaginal Lactobacillus crispatus IP 174178, used after antibiotic treatment, reduced BV recurrence from 41% to 20.5% — a clinically meaningful reduction. Similarly, research into Lactin-V (a specific L. crispatus strain) found that women using it after metronidazole had a 30% recurrence rate at 12 weeks, compared to 45% in the placebo group.

Not all probiotics are equal. This is a critical point. The research suggests strain-specific effects — L. crispatus and certain strains of L. rhamnosus appear most promising. Generic, multi-strain oral probiotics designed for gut health are a different product and cannot be assumed to confer the same vaginal benefits. Vaginal probiotic preparations that specifically target vaginal Lactobacillus recolonisation may offer more benefit.

The honest position is this: probiotics are generally safe, have a biologically sensible rationale, and the evidence is moving in a positive direction — particularly for recurrence prevention. They are not yet at the point of being a standard recommendation in all guidelines, but they are a reasonable add-on option to discuss with your doctor.

Boric Acid

Boric acid vaginal suppositories are an option worth understanding, particularly for recurrent BV. Boric acid works primarily by lowering vaginal pH — creating a more acidic environment that is less favourable to BV-associated bacteria — and may also have some biofilm-disrupting properties.

Important caveats:

• Boric acid is used vaginally only, as a suppository (a capsule inserted into the vagina). It must never be taken orally — it is toxic when swallowed.
• Boric acid is not safe in pregnancy — it is toxic to the developing foetus and should not be used if you are pregnant or could be pregnant.
• It should not be used if you have any cuts or open wounds in the vaginal area.

The current evidence in the published literature suggests boric acid may be useful as part of a broader management strategy for recurrent BV, particularly when combined with antibiotic treatment. In practice, it is sometimes used as part of a suppressive protocol: antibiotic treatment first, then a course of regular boric acid suppositories — which I have seen work well in my clinic.

If this is something you want to explore, please discuss it with your doctor first to make sure it is appropriate for your situation.

Vaginal Vitamin C

Vaginal vitamin C (ascorbic acid) works by acidifying the vaginal environment — essentially using the same principle as lactic acid gels, but with some evidence of more meaningful clinical effect.

A well-designed triple-blind randomised trial found that adding vaginal vitamin C tablets to oral metronidazole significantly improved outcomes: 87.7% cure rate at 30 days in the combined group, compared to 41.9% in the metronidazole-only group. A 2026 systematic review and meta-analysis found that intravaginal vitamin C may increase short-term cure rates and may support prevention of recurrence at 6 months, though the authors rated the overall certainty of evidence as low and called for further trials.

It is a relatively accessible, low-risk add-on option worth discussing with your doctor, particularly if you are dealing with recurrent BV.

Lactic Acid Gel

Lactic acid vaginal gels aim to restore vaginal acidity — the same mechanism as healthy Lactobacillus. The evidence suggests these products are less effective than antibiotics for acute BV treatment (achieving symptom resolution in around 47% of women versus 70% for metronidazole at two weeks), but they show comparable long-term recurrence rates over six months. They may have a role as maintenance products or for women who prefer to avoid antibiotics for mild symptoms.

A systematic review found that lactic acid products generally had medium to high risk of bias in the studies available, and did not significantly restore the vaginal microbiome composition — suggesting their effect may be more about pH modification than true microbiome restoration.

Plant-Based Products and Essential Oils — One to Watch

There is growing interest in plant-based topical products such as calendula (Calendula officinalis), myrtle (Myrtus communis), and barberry (Berberis vulgaris) gels and creams as potential alternatives or add-ons to standard treatment. Some small trials have reported symptom relief comparable to metronidazole, and laboratory studies suggest that certain essential oils and plant compounds may have biofilm-disrupting properties — which is biologically interesting given the central role of biofilms in BV recurrence.

The honest caveat: the evidence here is genuinely limited. Sample sizes are small, study quality is variable, and we are not yet at the point of being able to recommend any of these as a stand-alone option. This is a space to watch with cautious interest rather than something I would currently rely on. If you are drawn to exploring plant-based options, please do so alongside — not in place of — evidence-based care, and ideally in consultation with a practitioner who knows your full picture.

Partner Treatment

As mentioned earlier, the 2025 New England Journal of Medicine trial provides compelling evidence that treating male sexual partners with oral metronidazole and topical clindamycin cream significantly reduces BV recurrence — cutting recurrence rates nearly in half.

Current clinical guidelines have not yet formally adopted routine partner treatment as a recommendation, and this is an area where practice is actively evolving. But for women with recurrent BV in a monogamous heterosexual relationship, it is absolutely worth raising this research with your doctor and exploring whether partner treatment is appropriate for your situation.

Prevention Strategies Worth Knowing

While no single approach guarantees prevention, the following lifestyle habits are supported by evidence as likely to support a healthier vaginal ecosystem:

Stop douching. It disrupts the vaginal flora and increases BV risk. The vagina does not need to be cleaned internally.

Use condoms consistently. Condom use is associated with reduced BV risk, particularly worth considering in new or multiple partnerships.

Avoid harsh soaps in the vaginal area. External washing with plain water is sufficient. Scented products, intimate washes, and antiseptic soaps can all disrupt the local ecosystem.

Consider partner treatment. If you are in a monogamous relationship and experiencing recurrent BV, this conversation is worth having with your doctor.

Address vaginal oestrogen if you are peri- or postmenopausal. The hormonal environment matters. Local oestrogen therapy may support a healthier vaginal microbiome and reduce recurrence.

Look after your overall health. Smoking, stress, health diet and poor sleep all influence the immune and hormonal environment that shapes your vaginal health. These are not small factors.

A Word on Diagnosis in Perimenopause and Menopause

One thing I want to flag, because it genuinely affects women in this age group: diagnosis of BV can be more complicated in perimenopause and postmenopause.

The reason is that oestrogen decline alone causes elevated vaginal pH and reduced Lactobacillus — changes that look similar to BV on basic assessment. This means the classic Amsel criteria can produce more false positives in postmenopausal women. Some women may be diagnosed with BV and treated with repeated antibiotics when what they actually have is vaginal atrophy related to oestrogen deficiency.

If you are in perimenopause or beyond and experiencing recurrent vaginal symptoms, I'd encourage you to ask for a thorough assessment that considers both possibilities — and to ask specifically about local vaginal oestrogen as a management option if it hasn't already been discussed.

When to See a Doctor

Please see a healthcare provider if:

• You have any vaginal discharge that is unusual in colour, consistency, or smell
• You have symptoms of BV for the first time — to confirm the diagnosis and rule out other conditions including sexually transmitted infections
• Your BV is not resolving with treatment, or keeps coming back
• You are pregnant and have any vaginal symptoms (BV in pregnancy is associated with an increased risk of premature birth and other complications, and should always be assessed and treated)
• You are experiencing vaginal discomfort, dryness, or pain during sex in the context of perimenopause or menopause — there are effective treatments available that are often not proactively offered

The Bottom Line

BV is common. It is not shameful. It is not simply the result of poor hygiene or anything you have done wrong — those are outdated.

Coming back to that garden analogy: your vaginal ecosystem is a living, dynamic environment. When it gets out of balance — whether through hormonal shifts, sexual activity, antibiotics, or life's general stresses — the weeds can take over. Restoring the balance often takes more than just clearing the weeds; it means tending to the whole garden. That might mean treating partners, supporting healthy bacteria back in, addressing oestrogen, and gently rebuilding the soil over time.

When BV keeps coming back, that is a signal that the approach needs to go deeper than a single course of antibiotics. Understanding what is happening in your body is the first step toward changing it. And the more clearly you understand it, the more effectively you can have conversations with your healthcare providers about what you actually need.

If you would like personalised support with recurrent BV, vaginal health in perimenopause, or the connections between your hormonal health and your vaginal microbiome, I'd love to work with you. Book a consultation here.

Dr Taisia Cech

This article provides general educational information and is not personalised medical advice. Please consult your healthcare provider before making changes to your treatment, especially if you have medical conditions or are pregnant.

References

1. Bautista CT, Wurapa E, Sateren WB, Morris S, Hollingsworth B, Sanchez JL. Bacterial vaginosis: a synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections. Mil Med Res. 2016;3:4. doi:10.1186/s40779-016-0074-5

2. Coudray MS, Madhivanan P. Bacterial vaginosis — a brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143-148. doi:10.1016/j.ejogrb.2019.12.035

3. Chen X, Lu Y, Chen T, Li R. The female vaginal microbiome in health and bacterial vaginosis. Front Cell Infect Microbiol. 2021;11:631972. doi:10.3389/fcimb.2021.631972

4. Chacra L, Fenollar F, Diop K. Bacterial vaginosis: what do we currently know? Front Cell Infect Microbiol. 2022;11:672429. doi:10.3389/fcimb.2021.672429

5. Onderdonk AB, Delaney ML, Fichorova RN. The human microbiome during bacterial vaginosis. Clin Microbiol Rev. 2016;29(2):223-238. doi:10.1128/cmr.00075-15

6. Swidsinski S, Moll W, Swidsinski A. Bacterial vaginosis — vaginal polymicrobial biofilms and dysbiosis. Dtsch Arztebl Int. 2023. doi:10.3238/arztebl.m2023.0090

7. Machado A, Castro J, Palmeira-De-Oliveira A, Martinez-De-Oliveira J, Cerca N. Bacterial vaginosis biofilms: challenges to current therapies and emerging solutions. Front Microbiol. 2016;6:1528. doi:10.3389/fmicb.2015.01528

8. Committee on Practice Bulletins — Gynecology. Vaginitis in nonpregnant patients: ACOG Practice Bulletin, Number 215. Obstet Gynecol. 2020;135(1):e1-e17. doi:10.1097/AOG.0000000000003604

9. Fransanata H, Hidayati A. Understanding bacterial vaginosis: insights into definition, epidemiology, signs and symptoms, pathogenesis, risk factors, complications, diagnosis, and management. Int J Res Publ. 2023. doi:10.47119/ijrp1001401120245948

10. Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis. 2008;47(11):1426-1435. doi:10.1086/592974

11. Vodstrcil LA, Plummer EL, Doyle M, et al. Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial. BMC Infect Dis. 2020;20(1):924. doi:10.1186/s12879-020-05563-w

12. Vodstrcil LA, Plummer EL, Fairley CK, et al. Male-partner treatment to prevent recurrence of bacterial vaginosis. N Engl J Med. 2025;392(10):947-957. doi:10.1056/NEJMoa2405404

13. Morsli M, Gimenez E, Magnan C, et al. The association between lifestyle factors and the composition of the vaginal microbiota: a review. Eur J Clin Microbiol Infect Dis. 2024;43:1869-1881. doi:10.1007/s10096-024-04915-7

14. Richman M, Nasir R, Guilherme S, et al. Bacterial vaginosis: a review of pathophysiology, epidemiology, complications, diagnosis, and treatment. Europasian J Med Sci. 2023. doi:10.46405/ejms.v5i1.475

15. Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas. 2016;91:42-50. doi:10.1016/j.maturitas.2016.05.015

16. De Oliveira NF, De Lima AJ, De Brito JA, Sarmento AJ, Gonçalves AK, Eleutério J. Postmenopausal vaginal microbiome and microbiota. Front Reprod Health. 2022;3:780931. doi:10.3389/frph.2021.780931

17. Kaur H, Merchant M, Haque MM, Mande SS. Crosstalk between female gonadal hormones and vaginal microbiota across various phases of women's gynecological lifecycle. Front Microbiol. 2020;11:551. doi:10.3389/fmicb.2020.00551

18. Lin W, Wang L, Dong B, et al. Age-related vaginal microecology and infection epidemiology among premenopausal and postmenopausal gynecologic outpatients: a cross-sectional study. Front Cell Infect Microbiol. 2025;15:1569667. doi:10.3389/fcimb.2025.1569667

19. Van Gerwen OT, Smith SH, Muzny CA. Bacterial vaginosis in postmenopausal women. Curr Infect Dis Rep. 2023;25:7-15. doi:10.1007/s11908-022-00794-1

20. Shardell M, Gravitt P, Burke A, Ravel J, Brotman R. Association of vaginal microbiota with signs and symptoms of the genitourinary syndrome of menopause across reproductive stages. J Gerontol A Biol Sci Med Sci. 2021. doi:10.1093/gerona/glab120

21. Zeng Q, Shu H, Pan H, et al. Associations of vaginal microbiota with the onset, severity, and type of symptoms of genitourinary syndrome of menopause in women. Front Cell Infect Microbiol. 2024;14:1402389. doi:10.3389/fcimb.2024.1402389

22. Shen J, Song N, Williams CJ, et al. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep. 2016;6:24380. doi:10.1038/srep24380

23. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1

24. Sobral MN, Soares V, Moreira J, et al. Tinidazole vs metronidazole for the treatment of bacterial vaginosis: a systematic review and meta-analysis. Arch Gynecol Obstet. 2025;311:333-340. doi:10.1007/s00404-024-07899-z

25. Faught BM, Reyes S. Characterization and treatment of recurrent bacterial vaginosis. J Womens Health. 2019;28(9):1218-1226. doi:10.1089/jwh.2018.7383

26. Chieng WK, Jalal MIA, Bedi JS, et al. Probiotics, a promising therapy to reduce the recurrence of bacterial vaginosis in women? A systematic review and meta-analysis of randomized controlled trials. Front Nutr. 2022. doi:10.3389/fnut.2022.938838

27. Chen R, Li R, Qing W, et al. Probiotics are a good choice for the treatment of bacterial vaginosis: a meta-analysis of randomized controlled trials. Reprod Health. 2022;19:137. doi:10.1186/s12978-022-01449-z

28. Ma S, Wang W, Su Y, et al. Antibiotics therapy combined with probiotics administered intravaginally for the treatment of bacterial vaginosis: a systematic review and meta-analysis. Open Med. 2023. doi:10.1515/med-2023-0644

29. Bohbot JM, Daraï E, Bretelle F, et al. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. J Gynecol Obstet Hum Reprod. 2018;47(2):81-86. doi:10.1016/j.jogoh.2017.11.005

30. Cohen CR, Wierzbicki MR, French AL, et al. Randomized trial of Lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med. 2020;382(20):1906-1915. doi:10.1056/NEJMoa1915254

31. Udjianto U, Sirat NA, Rahardjo B, Zuhriyah L. Effective probiotic regimens for bacterial vaginosis treatment and recurrence prevention: a systematic review. Narra J. 2025;5(1). doi:10.52225/narra.v5i1.1671

32. Chow KW, Wooten D, Annepally S, et al. Impact of (recurrent) bacterial vaginosis on quality of life and the need for accessible alternative treatments. BMC Womens Health. 2023;23:301. doi:10.1186/s12905-023-02236-z

33. Abbe C, Mitchell C. Bacterial vaginosis: a review of approaches to treatment and prevention. Front Reprod Health. 2023;5:1100029. doi:10.3389/frph.2023.1100029

34. Mohammad-Alizadeh S, Dokhanchi T, Hakimi S, et al. The addition of vitamin C vaginal tablets to oral metronidazole and its effect on the treatment and recurrence of bacterial vaginosis: a randomized triple-blind clinical trial. Int J Womens Health Reprod Sci. 2017. doi:10.15296/ijwhr.2017.35

35. Khaikin Y, Elangainesan P, Winkler E, et al. Intravaginal vitamin C for the treatment and prevention of bacterial vaginosis: a systematic review and meta-analysis. Obstet Gynecol. 2026;147(4):491-500. doi:10.1097/AOG.0000000000006092

36. Armstrong-Buisseret L, Brittain C, Kai J, et al. Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT. Health Technol Assess. 2022. doi:10.3310/ZZKH4176

37. Plummer EL, Bradshaw CS, Doyle M, et al. Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: a systematic review. PLoS ONE. 2021. doi:10.1371/journal.pone.0246953

38. Cauci S, Driussi S, De Santo D, et al. Prevalence of bacterial vaginosis and vaginal flora changes in peri- and postmenopausal women. J Clin Microbiol. 2002;40(6):2147-2152. doi:10.1128/jcm.40.6.2147-2152.2002

39. Sousa LG, Pereira SA, Cerca N. Fighting polymicrobial biofilms in bacterial vaginosis. Microb Biotechnol. 2023;16(7):1423-1437. doi:10.1111/1751-7915.14261